Evidence map›Paper›PMID 33959600›Full record

ReviewFrontiers in bioengineering and biotechnology2021

Engineering Cardiovascular Tissue Chips for Disease Modeling and Drug Screening Applications.

Alex H P Chan, Ngan F Huang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Tissue chips as headway model and incitement technology.Synthetic and systems biotechnology · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alex H P ChanDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, United States.
Ngan F HuangDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, United States.
Cardiovascular Institute of the South · USStanford University · US

Funding

UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD005978 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2016 to 2025
$34.5M
Aligned Nanofibrillar Scaffolds Enhance Angiogenesis and Viability in Ischemia: Sex Differences Administrative SupplementR01HL127113 · NHLBI · STANFORD UNIVERSITY · PI HUANG, NGAN F. · 2016 to 2020
$2.5M
Engineered matrix microarrays to enhance the regenerative potential of iPSC-derived endothelial cellsR01HL142718 · NHLBI · STANFORD UNIVERSITY · PI HEILSHORN, SARAH C, HUANG, NGAN F. · 2018 to 2021
$1.6M
Vascularized Cardiac Patch with Physiological Orientation for Myocardial RepairI01BX002310 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HUANG, NGAN F. · 2015 to 2018
–
Engineering Vascularized Skeletal Muscle for Treatment of Volumetric Muscle LossI01BX004259 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI Ngan F. Huang · 2019 to 2026
–
BLRD VA I01 BX002310BLRD VA I01 BX004259FDA HHS U01 FD005978NHLBI NIH HHS R01 HL127113NHLBI NIH HHS R01 HL142718RRD VA I01 RX001222
6 · The paper itself

Abstract

In recent years, the cost of drug discovery and development have been progressively increasing, but the number of drugs approved for treatment of cardiovascular diseases (CVDs) has been limited. Current

Indexed as

bioengineering (general)cardiovasculardisease modelingiPSCtissue chip

Identifiers

PMID33959600
PMCPMC8093512
OpenAlexW3154621290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.